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Th cells are involved in induction of CTL (1). As in the case of hapten-carrier
conjugates, it is generally assumed that CTL, and the Th cells that help them, re-
spond to different epitopes . This expectation is supported by the fact that in most
cases, Th cells express CD4 and are restricted by class II MHC molecules, whereas
conventional CTL express CD8 and are restricted by class I MHC molecules. Tar-
geting different classes of MHC molecules increases the likelihood of recognition
ofdifferent processed antigen fragments. In addition, the class I and class II MHC
molecule-restricted antigen processing pathways are thought to be different (2).
The epitopes of proteins can be defined with short synthetic peptides for both
class I-restricted CTL (3) and class II-restricted Th cells (4). We have recently
identified an immunodominant CTL epitope from the HIV1-IIIB envelopeprotein
gp160 comprisingthe 15 amino acids (315-329) (RIQRGPGRAFVTIGK) (18IIIB)
and recognized by class I MHC molecule (D')-restricted murine CD4- CD8+ CTL
(5). In our original work, mice were immunized with recombinant vaccinia virus
expressing the HIV1-IIIB gp160 envelope gene (vSC25) (6), and theirlymphocytes
were restimulated in vitro with a transfected histocompatible cell line expressing
gp160IIIB (5). We now show that we can stimulate spleen cells from immune mice
to make CTL in vitro with peptide alone, without exogenous lymphokine. We find
that during in vitro stimulation with synthetic peptide corresponding to the CTL
antigenic determinant, a class II MHC-restricted CD4+ Th cell response against
the samepeptidecontributes to the induction ofCTL. Thus, thesame peptidestructure
induces both class II MHC molecule-restricted CD4+ Th cells and class I mole-
cule-restricted CD8+ CTL. We speculate on the significance of this dual function
for the immunodominance of this CTL determinant in the HIV envelope.
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Mice.
￿
BALB/c, B10.D2, and B10.A/SgSn mice were obtained from The Jackson Labora-
tory (Bar Harbor, ME). Mice were used at 6-12 wk of age for immunization.
Recombinant Vaccinia Viruses.
￿
vSC-8 (recombinant vaccinia vector containing the bacterial
lacZ gene), and vSC-25 (recombinant vaccinia vector expressing the HIV env glycoprotein
gp160 of the IIIB isolate) have been described previously (6).
Transfectants.
￿
BALB/c-3T3 (H-2d) fibroblast transfectants expressing HIV-1 IIIB gp160
and control transfectants with only the selectable marker gene were derived as described (5).
mAbs.
￿
The following mAbs were used: anti-L3T4 (CD4) (RL172.4; rat IgM) (7), anti-
Ad,Ed (M5/114; rat IgG2b) (8), anti-Ad (MK-D6) (9), and anti-Ea'd (14-4-4) (10).
Peptide Synthesis and Purification.
￿
Peptide 18IIIB was synthesized by solidphasetechniques
by Peninsula Laboratories, Inc. (Belmont, CA), and purified by gel filtration and ion ex-
change chromatography. The purified peptide was a single peak on reverse phase HPLC on
C-18 columns with two different solvent systems, trifluoroacetic acid/water/acetonitrile, and
0.05 M NaH2PO4/acetonitrile, and had the expected amino acid analysis.
CTL Generation.
￿
Mice were immunized intravenously with 10' PFU of recombinant vac-
cinia viruses. 3-20 wk later, immune spleen cells (5 x 106/ml in 24-well culture plates in
complete T cell medium [5]) were restimulated for 6 d in vitro with either 0.3 AM of im-
munodominant peptide for CTL from HIV-1-111B gp160 envelope glycoprotein (18111B)
(RIQRGPGRAFVTIGK) (5) alone, 18IIIB plus 10% rat Con A supernatant-containing
medium (rat T cell Monoclone) (Collaborative Research, Lexington, MA), or 18IIIB plus
10 U/ml of mouse rIL-2 (Genzyme, Boston, MA).
CTL Assay.
￿
After culture for 6 d, cytolytic activity of the restimulated cells was measured
usinga 6-h assay with various "Cr-labeled targets (5). Percent specific 5'Cr release was cal-
culated as 100 x (experimental release - spontaneous release)/(maximum release - sponta-
neous release). Maximum release was determined from cells lysed by addition of5 % Triton-
X 100, and spontaneous release from target cells incubated alone. SEMs oftriplicate cultures
were always <5o7o of the mean.
Results and Discussion
Peptide 18IIIB Is Sufficientfor Induction ofgp160- and Peptide 18IIIB-speck CTLfrom
Immune Spleen Cells in H-2d Mice. When we originally induced gp160IIIB-specific
CTL, mice were immunized with recombinant vaccinia virus carrying the HIV1-
IIIB gp160 envelope gene (vSC25), and their immune spleen cellswere restimulated
with gpl60-transfected BALB/c.3T3 fibroblasts (5). Here we show that we can elicit
CTL specific for the immunodominant site when vSC25-immune BALB/c spleen
cells are restimulated in vitro with peptide 1811IB alone (Fig. 1). Mice immunized
with control vaccinia virus (vSC8) showed no significant cytotoxic activity after in
vitro restimulation with any ofthe forms ofthe antigen (datanot shown). Therefore,
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FIGURE 1.
￿
BALB/c mice (Ad, Ed, and Dd) were
immunized intravenously with 10' PFU of recom-
binant vaccinia virusexpressing HIVl-IIIB gp160
gene (vSC25). 3-20 wk later, immune spleen cells
(5 x 106/ml) were restimulated for 6 d in vitro with
0.3 pM of peptide 181IIB alone in 24-well culture
plates. Cytolytic activity oftherestimulated cellswas
measured with the indicated "Cr-labeled targets:
1 AM peptide 18IIIB-pulsed BALB/c.3T3 fibroblast
targets(*); HIVl-IIIB gp160 gene- transfected
BALB/c.3T3 (E); and control unpulsed BALB/c.3T3
fibroblasts (O).u
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immunization with vSC25 isnecessarytoelicitCTL specificfortheimmunodominant
site, but the synthetic peptide is sufficient for restimulation of CTL in vitro. The
CTL induced in this system are CD4- CD8+, based on lysis with anti-CD4 or anti-
CD8 and C(5), and lyse class 11- fibroblast targets.
Depletion ofCD4' Cellsfrom Immune Spleen Cells Abrogates In Vitro Peptide-stimulated
CTL Induction, which Is Restored by IL-2. To determine the role ofCD4' cells in the
induction ofCTL by peptide 18IIM, we depleted CD4' cells from the spleen cells
ofvSC25-immune BALB/c mice by treatment with anti-CD4 mAb (RL172.4) plus
C. CD4' cell depletion nearly completely abrogated induction ofspecific CTL by
restimulation in vitro with peptide 18IIIB (Fig. 2). However, this activity was com-
pletely restored by inclusion ofIL-2 in the restimulation culture (Fig. 2). 1310 .D2
mice gave the same results (data not shown). Thus, CD4* cells are necessary to in-
duce classI MHC molecule-restricted peptide-specific CTL, and this function can
be replaced by exogenous IL-2. Furthermore, vSC25-immune BALB/c spleen cells
restimulated in vitro with onlypeptide 18IIIB secretedIL-2(datanot shown). Without
depletion ofCD4' cells, IL-2 produced little or no further enhancement ofthe re-
sponse (see Table I, below). Therefore, the function of the CD4' cells appears to
be Tcell help. The results also suggest that peptide 1811113, the immunodominant
site for CTL restricted by the Dd class I MHC molecule, also induces CD4+ Th
cells likely to recognize antigen with class II MHC molecules. Therefore, we tested
whethermAbs to Ad and Ed could block the activation ofTh cells by peptide 18IIIB.
The Effect ofAntiAd and/or EmAb on CTL Induction.
￿
When the vSC25-immu-
nized BALB/c spleen cells were restimulated with peptide 18IIIB in the presence
ofa mAb (M5/114) specific for both Ad and Ed, specific CTL induction was greatly
reduced (Table I, Exp. 1). However, little or no inhibition of the CTL induction
was produced by M5/114 in the presence ofIL-2, indicating: (a) that the antibody
was not nonspecifically toxic; and (b) that the effect ofM5/114 was to inhibit induc-
tion of T cell help, not some other aspect of CTL induction. To further map the
class II MHC restriction ofTh cells for peptide 1811113, we used MK-D6 (anti-I-
Ad) and 14-4-4 (anti-I-Ed/k) mAbs that were retested for specific blocking activity
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FIGURE 2.
￿
Spleen cells from BALB/c mice immunized with 10' PFU of vSC25 were treated
with anti-CD4 mAb(RL172 .4) plus complement and restimulated in vitro with either 0.3 ,UM
ofpeptide 18I1IB alone(A)or 0.3 uM of 18IIIB plus IL-2 (10% ofrat Tcell monocloneor mouse
rIL-2 (B). After a6-d culture, cytotoxic activities were tested against the indicated "Cr-labeled
targets: 1 PM 1811113-pulsed BALB/c.3T3 fibroblasts ("); HIVl-IIIB gp160 gene-transfected
BALB/c.3T3 (/); and control Impulsed BALB/c.3T3 fibroblasts (O).574
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TABLE I
Mapping of Class II MHC Restriction ofpeptide 18IIIB Induction of T Cell Help
BALB/c.3T3 cells expressing transfected gp160 (IIIB) gene.
t Underscored data represent >60% inhibition.
Targets (percent specific lysis)
(data not shown) with myoglobin-specific T cell clones restricted by I-Ad and I-Ed.
The results showed that the Th cells stimulated by peptide 18IIIB were restricted
by the class II Ad molecule (Table I, Exp. 2). Therefore, peptide 18IIIB, which con-
tains an immunodominant site for class I Dd molecule-restricted CTL, also con-
tains a Th cell epitope presented by the class II Ad MHC molecule. Although we
cannot be sure at this stage that the residues responsible for binding Dd and Ad are
the same, the antigenic sites presented by class I and class II MHC molecules are
likely to overlap extensively because the peptide is only 15 residues long.
Peptide 18IIIB Fails to Stimulate CTL in Immune Spleen Cellsfrom B10.A Mice (Ak, Ek,
Dd). Because we found that H-2d mice are CTL high responders, whereas H-2k
mice are low responders to HIV gp160 (5), it was of interest to test whethercongenic
B10.A mice, which have the appropriate class I Dd, but the class II molecules Ak
and Ek of the low responder strain, can produce specific CTL when their vSC25-
immune spleen cells are restimulated in vitro with peptide 18IIIB. Fig. 3 shows that
restimulation with peptide 18IIIB alonecould not elicit specific CTL at all in B10.A
mice, in contrast to BALB/c mice (Fig. 1) or B10.D2 mice (data not shown). How-
ever, restimulation with 18IIIB plus IL-2 produced CTL specific for this im-
munodominant site (Fig. 3). Thus, immune B10.A spleen cells without any CD4
cell depletion behaved identically to BALB/c spleen cells after CD4 cell depletion
(compare with Fig. 2). They appear to lack T cell help specific for peptide 18IIIB.
Pfizenmaier et al. (11) have reported that the CTL response to SV40 tumor-as-
sociated specific antigens is associated with Kb, Kk, Db, and Dd, but not with Kd
or Dk, and that B10.D2 mice (Ad, Ed, and Dd) could generate Dd-restricted CTL,
but B10.A mice (Ak, Ek, and Dd) could not. However, BRA mice could induce Kk-
restricted CTL. Therefore, they speculated that T cell help would be provided pref-
erentially to those CTL recognizingclass I molecules of the same haplotype as class
Exp.
E/T ratio
Immunization/
Restimulation Additions
HIV-gp160
TF'
40/1 20/1
18IIIB-
pulsed
BALB/c.3T3
40/1 20/1
Unpulsed
BALB/c.3T3
40/1 20/1
1 vSC25/18IIIB 29.1 27.6 81 .2 70.4 11 .8 4.5
vSC25/18IIIB M5/114 (10%) 9 .41 5.0 13.7 6.3 -5.9 -5 .7
vSC25/18IIIB M5/114 (3%) 17 .4 13 .9 49.2 37.2 -3.0 -6.4
vSC25/18IIIB + IL-2 24.4 23 .9 86.8 84.6 2.9 -0.1
vSC25/18IIIB + IL-2 M5/114 (10%) 20.9 14 .4 70.2 53.1 7.6 1 .7
vSC25/18IIIB + IL-2 M5/114 (3%) 23.6 22 .2 87 .0 83 .5 13.9 7.5
2 vSC25/18IIIB 46.6 35 .4 80.2 76 .9 6.7 5.3
vSC25/18IIIB MK.D6 (25%) 11 .7 3 .8 27 .6 15 .2 1.0 1 .2
vSC25/18IIIB 14.4.4 (10%) 46.8 38.2 83 .0 80 .6 7.1 5.6
vSC25/18IIIB + IL-2 45.3 41 .0 94.0 89 .1 8.9 5.8
vSC25/18IIIB + IL-2 MK.D6 (25%) 41 .3 33.1 92 .7 81 .5 4 .2 1 .9
vSC25/18IIIB + IL-2 14.4.4 (10%) 51 .3 42.3 94.5 88.7 9 .8 5.8TAKAHASHI ET AL.
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FIGURE 3.
￿
Peptide 18IIIB does notgenerate help in B10.A
mice. Spleen cells from B10.A mice (Ak, Ek, and Dd) im
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fibroblast targetseither pulsed with 1 ttMof 18IIIB (closed
symbols) or unpulsed (open symbols). HIV-1 gp160-transfected
targets (not shown) gave results similar to thoseof peptide-
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II MHC molecules. Our current data support the speculation, and moreover, we
found that the same epitope was seen by both class I and class II MHC molecules
from the same haplotype.
There are now a few examples in the literature in which the same peptide is seen
bydifferentT cells with multiple alleles ofthe same class II molecule (12), withboth
isotypes ofclass II molecule (13), or even with both classes ofMHC molecules (14).
However, these various studies donot show a functional importanceto this degenerate
presentation. In the current study, not only is the same peptide seen by Tcells in
association with both class I and class II molecules, after in vivo processing of the
native protein, but also, these MHC molecules are associated in the samehaplotype
so that the same small peptide can induce help for a CTL response to itself.
Finally, we would like to speculate that the same antigenic site of pathogens is
sometimes presented by both class I and class II MHC molecules. If these class I
and class II molecules are shared by the same MHC haplotype, this dual presenta-
tion of the same (or closely overlapping) antigenic site may contribute to its im-
munodominance. Conversely, such relationships betweenclass I and II MHC mole-
cules might provide some selective advantage to the maintenance of certain
combinations in haplotypes, and therefore contribute tolinkagedisequilibrium within
the MHC.
Summary
We have observed that a peptide corresponding to an immunodominant epitope
ofthe HIV-1 envelope protein recognized by class I MHC-restricted CD8+ CTL
can also induce T cellhelp for itself. The help is necessary for restimulation ofCTL
precursors in vitro with peptide alone in the absence of exogenous lymphokines,
can be removed by depletion of CD4+ T cells, and can be replaced by exogenous
IL-2. Whereas the CTL in BALB/c or B10.D2 mice are restricted by the class I mol-
ecule Dd, the Th cells are restricted by the class II molecule Ad, and the help can
be blocked by anti-Ad mAb. To examine the genetic regulation of the induction of
help, we studied B10.A mice that share the class I Dd molecule, but have different
class II molecules, Ak and Ek. Spleen cells ofimmune B10.A mice behave like CD4-
depleted BALB/c spleen cells in that they cannot be restimulated in vitro by the
peptide alone, but can with peptide plus IL-2. Therefore, in the absence of exoge-
nous lymphokines, peptide-specific help is necessary for restimulationwith this im-
munodominant CTL epitope peptide, and in H-2d mice, this peptide stimulates
help for itself as well as CTL. We speculate on the implications of these findings576
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for the immunodominance of this peptide in H-2a mice, and for the selective ad-
vantage of pairing certain class I and class II molecules in an MHC haplotype.
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